To RAS or Not to RAS? The evidence for and cautions with Renin-Angiotensin system inhibition in patients with diabetic kidney disease

Pharmacotherapy

Volumn 33, Issue 5, 2013, Pages 496-514

  St Peter, Wendy L ^a   Odum, Lauren E ^b   Whaley Connell, Adam T ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c University of Missouri   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Diabetic kidney disease; Renin angiotensin system inhibition

Indexed keywords

ALBUMIN; ALDOSTERONE; ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LOSARTAN; OLMESARTAN; PLACEBO; POTASSIUM; RAMIPRIL; RENIN; RENIN INHIBITOR; TELMISARTAN;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; COUGHING; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG TOLERABILITY; HORMONE INHIBITION; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY HYPERTROPHY; MACROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FUNCTION TESTS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84879600350     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1232     Document Type: Review

References (78)

1. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care 2013;36(Suppl 1):S11-S66.
2. U.S. Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, 2011 ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
3. De Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-2539.
4. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-1720.
5. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
7. Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 2006;20: 239-253.
8. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006;Issue 4, Art. No.CD006257.
9. Hirst JA, Taylor KS, Stevens RJ, et al. The impact of reninangiotensin- aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int 2012;81:674-683.
10. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48.
11. Centers for Disease Control and Prevention. Diagnosed diabetes: number and percentage of U.S. population with diagnosed diabetes. Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5544a4.htm. Accessed July 10, 2012.
12. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
13. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
14. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012;55: 566-578.
15. Yerram P, Karuparthi PR, Hesemann L, Horst J, Whaley-Connell A. Chronic kidney disease and cardiovascular risk. J Am Soc Hypertens 2007;1:178-184.
16. Botdorf J, Chaudhary K, Whaley-Connell A. Hypertension in cardiovascular and kidney disease. Cardiorenal Med 2011;1:183-192.
17. Hayden MR, Sowers KM, Pulakat L, et al. Possible mechanisms of local tissue renin-angiotensin system activation in the cardiorenal metabolic syndrome and type 2 diabetes mellitus. Cardiorenal Med 2011;1:193-210.
18. Nicholas SB. Advances in pathogenetic mechanisms of diabetic nephropathy. Cell Mol Biol (Noisy-le-grand) 2003;49:1319-1325.
19. Nistala R, Whaley-Connell A, Sowers JR. Redox control of renal function and hypertension. Antioxid Redox Signal 2008;10:2047-2089.
20. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-287.
21. Liu Z, Huang XR, Chen HY, Penninger JM, Lan HY. Loss of angiotensin-converting enzyme 2 enhances TGF-beta/Smadmediated renal fibrosis and NF-kappaB-driven renal inflammation in a mouse model of obstructive nephropathy. Lab Invest 2012;92:650-661.
22. Chen J, Chen JK, Harris RC. Angiotensin II induces epithelial- to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol 2012;32:981-991.
23. Sofue T, Kiyomoto H, Kobori H, et al. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens 2012;25:604-611.
24. Fujiwara K, Hayashi K, Matsuda H, et al. Altered pressurenatriuresis in obese Zucker rats. Hypertension 1999;33:1470-1475.
25. Manns B, Hemmelgarn B, Tonelli M, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ 2010;341:c5869.
26. Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012;156:570-581.
27. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;3: 1-150.
28. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(Suppl 2):S1-S180.
29. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-886.
30. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2012;2:337-414.
31. U.S. Department of Health & Human Services. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Available from http://www.nhlbi.nih.gov/guidelines/ hypertension/jnc7full.pdf. Accessed July 10, 2012.
32. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
33. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
34. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Followup Program Cooperative Group. Hypertension 1989;13:I80-I93.
35. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. JAMA 1992;268(21):3085-3091.
36. Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995;25:587-594.
37. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-252.
38. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO reaches consensus on CKD staging. Available from http://www.kdigo.org/news-KDIGO-Consensus-on- CKD-Staging.php. Accessed July 13, 2012.
39. Kidney Disease Improving Global Outcomes (KDIGO). Kidney Disease: Improving Global Outcomes (KDIGO). Available from http://www.kdigo.org/clinical- practice-guidelines/ckd.phpews-KDIGO-Consensus-on-CKD-Staging.php. Accessed July 13, 2012.
40. Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guidelines: published KDIGO clinical practice guidelines. Available from http://www.kdigo.org/clinical-practice-guidelines/index.php. Accessed July 10, 2012.
41. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
42. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-2728.
43. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997;30:428-435.
44. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensinconverting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936-946.
45. Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006;144:172-180.
46. Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012;59:74-83.
47. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-68.
48. National Institutes of Health. Systolic Blood Pressure Intervention Trial (SPRINT). Available from http://clinicaltrials.gov/ct2/show/NCT01206062. Accessed July 11, 2012.
49. Healthy People 2020. Healthy People 2020 Topics and Objectives: Chronic Kidney Disease. Available from http://www.healthypeople.gov/2020/ topicsobjectives2020/objectiveslist.aspx?topicid=6. Accessed July 13, 2012.
50. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51.
51. Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-14.
52. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011;54:2978-2986.
53. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-917.
54. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 2006;26:635-vii.
55. Chugh A, Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update J Clin Hypertens (Greenwich) 2007;9:196-200.
56. Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009;54:205-226.
57. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-988.
58. Persson F, Rossing P, Reinhard H, et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 2010;53:1576-1580.
59. U.S. Food and Drug Administration. FDA drug safety communication: safety review update of benicar (olmesartan) and cardiovascular events. Available from http://www.fda.gov/drugs/drugsafety/ucm251268.htm. Accessed July 10, 2012.
60. Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med 2006;119:S40-S47.
61. Arici M, Erdem Y. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Am J Kidney Dis 2009;53:332-345.
62. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124.
63. Anonymous. Retraction-Combination treatment of angiotensin- II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009;374:1226.
64. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005;45:880-886.
65. Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007;72:879-885.
66. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double- blind, controlled trial. Lancet 2008;372:547-553.
67. Krairittichai U, Chaisuvannarat V. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. J Med Assoc Thai 2009;92:611-617.
68. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446.
69. Ku E, Park J, Vidhun J, Campese V. The hazards of dual renin-angiotensin blockade in chronic kidney disease. Arch Intern Med 2009;169:1015-1018.
70. Ruggenenti P, Remuzzi G. Proteinuria: is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009;5:436-437.
71. Fried LF, Duckworth W, Zhang JH, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009;4:361-368.
72. National Institutes of Health. VA NEPHRON-D: Diabetes iN Nephropathy Study. Available from http://clinicaltrials.gov/ct2/show/results/NCT00555217. Accessed July 10, 2012.
73. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010;33:2304-2309.
74. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671.
75. Novartis. Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in high-risk patients with diabetes and renal impairment. Available from http://www.novartis.com/ newsroom/media-releases/en/ 2011/1572562.shtml. Accessed July 10, 2012.
76. U.S. Food and Drug Administration. FDA drug safety communication: new warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). Available from http://www.fda.gov/drugs/drugsafety/ucm300889.htm. Accessed July 10, 2012.
77. Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med 2007;357:797-805.
78. St Peter WL, Farley TM, Carter BL. Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients. Curr Opin Nephrol Hypertens 2011;20:498-503.